{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:04:34Z","timestamp":1773461074765,"version":"3.50.1"},"reference-count":26,"publisher":"Japanese Circulation Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.1253\/circrep.cr-25-0254","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:09:09Z","timestamp":1766786949000},"page":"486-494","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm"],"prefix":"10.1253","volume":"8","author":[{"given":"Miku","family":"Hirose","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Hospital"},{"name":"Department of Advanced Medicine, Nagoya University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Meijyo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. O\u2019Sullivan J, Mead AJ. Heterogeneity in myeloproliferative neoplasms: Causes and consequences. <i>Adv Biol Regul<\/i> 2019; 71: 55\u201368.","DOI":"10.1016\/j.jbior.2018.11.007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Weatherald J, Savale L, Humbert M. Medical management of pulmonary hypertension with unclear and\/or multifactorial mechanisms (Group 5): Is there a role for pulmonary arterial hypertension medications? <i>Curr Hypertens Rep<\/i> 2017; 19: 86.","DOI":"10.1007\/s11906-017-0783-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Montani D, Thore P, Mignard X, Jais X, Boucly A, Jevnikar M, et al. Clinical phenotype and outcomes of pulmonary hypertension associated with myeloproliferative neoplasms: A population-based study. <i>Am J Respir Crit Care Med<\/i> 2023; 208: 600\u2013612.","DOI":"10.1164\/rccm.202210-1941OC"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Eichstaedt CA, Verweyen J, Halank M, Benjamin N, Fischer C, Mayer E, et al. Myeloproliferative diseases as possible risk factor for development of chronic thromboembolic pulmonary hypertension: A genetic study. <i>Int J Mol Sci<\/i> 2020; 21: 3339.","DOI":"10.3390\/ijms21093339"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K, et al. Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. <i>Nat Commun<\/i> 2021; 12: 6177.","DOI":"10.1038\/s41467-021-26435-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. <i>Blood<\/i> 2021; 137: 2152\u20132160.","DOI":"10.1182\/blood.2020008109"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ikeda N, Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, et al. Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: Findings from the CTEPH AC registry. <i>Cardiovasc Interv Ther<\/i> 2025; 40: 689\u2013700.","DOI":"10.1007\/s12928-025-01095-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tabuchi I, Ogawa A, Shigetoshi M, Shimokawahara H, Ito H, Matsubara H. Low incidence of restenosis after successful balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. <i>Cardiovasc Interv Ther<\/i> 2023; 38: 231\u2013240.","DOI":"10.1007\/s12928-022-00866-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fujii S, Nagayoshi S, Matsumoto T, Miyamoto T, Ogawa K, Yoshimura M. Spontaneous hemodynamic improvement after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension is observed within a short term after balloon pulmonary angioplasty. <i>Cardiovasc Interv Ther<\/i> 2024; 39: 302\u2013313.","DOI":"10.1007\/s12928-024-00987-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D\u2019Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. <i>Circulation<\/i> 2016; 133: 859\u2013871.","DOI":"10.1161\/CIRCULATIONAHA.115.016522"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wiedenroth CB, Rolf A, Steinhaus K, Adameit MSD, Kriechbaum SD, Haas M, et al. Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. <i>J Heart Lung Transplant<\/i> 2023; 42: 134\u2013139.","DOI":"10.1016\/j.healun.2022.08.011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Results of a multicenter registry. <i>Circ Cardiovasc Qual Outcomes<\/i> 2017; 10: e004029, doi:10.1161\/CIRCOUTCOMES.117.004029.","DOI":"10.1161\/CIRCOUTCOMES.117.004029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>Eur Heart J<\/i> 2016; 37: 67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J<\/i> 2022; 43: 3618\u20133731.","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"15","unstructured":"15. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Lyon: International Agency for Research on Cancer, 2017."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ferrari A, Scandura J, Masciulli A, Krichevsky S, Gavazzi A, Barbui T. Prevalence and risk factors for pulmonary hypertension associated with chronic myeloproliferative neoplasms. <i>Eur J Haematol<\/i> 2021; 106: 250\u2013259.","DOI":"10.1111\/ejh.13543"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Guth S, D\u2019Armini AM, Delcroix M, Nakayama K, Fadel E, Hoole SP, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: Results of the worldwide prospective CTEPH Registry. <i>ERJ Open Res<\/i> 2021; 7: 00850-2020, doi:10.1183\/23120541.00850-2020.","DOI":"10.1183\/23120541.00850-2020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mercier O, Dubost C, Delaporte A, Genty T, Fabre D, Mitilian D, et al. Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. <i>Ann Cardiothorac Surg<\/i> 2022; 11: 143\u2013150.","DOI":"10.21037\/acs-2021-pte-20"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated phase of myeloproliferative neoplasms. <i>Acta Haematologica<\/i> 2021; 144: 484\u2013499.","DOI":"10.1159\/000512929"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: A population-based cohort study. <i>Ann Intern Med<\/i> 2018; 168: 317\u2013325.","DOI":"10.7326\/M17-0028"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, Kobayashi Y, et al. Newly diagnosed cancer after diagnosis of venous thromboembolism: Insights from the COMMAND VTE Registry-2. <i>Circ J<\/i> 2024, doi:10.1253\/circj.CJ-24-0786.","DOI":"10.1253\/circj.CJ-24-0786"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. <i>N Engl J Med<\/i> 2013; 368: 22\u201333.","DOI":"10.1056\/NEJMoa1208500"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration Data. <i>Clin Lymphoma Myeloma Leuk<\/i> 2020; 20: 63\u201369.","DOI":"10.1016\/j.clml.2019.11.010"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, et al. Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. <i>Eur J Haematol<\/i> 2018; 101: 131\u2013135.","DOI":"10.1111\/ejh.13070"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ikeda S, Yamashita Y, Morimoto T, Chatani R, Kaneda K, Nishimoto Y, et al. Association between white blood cell counts at diagnosis and clinical outcomes in venous thromboembolism: From the COMMAND VTE Registry-2. <i>Circ J<\/i> 2025; 89: 592\u2013601.","DOI":"10.1253\/circj.CJ-24-0581"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Komura N, Sugano T, Ono F, Nakayama M, Suzuki T, Kawaura N, et al. Effect of balloon pulmonary angioplasty on chronic thromboembolic pulmonary hypertension: An assessment of the learning curve in a Japanese university hospital. <i>Cardiovasc Interv Ther<\/i> 2025; 40: 389\u2013399.","DOI":"10.1007\/s12928-024-01076-4"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/3\/8_CR-25-0254\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:20:29Z","timestamp":1773458429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/3\/8_CR-25-0254\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0254","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"CR-25-0254"}}